Treatment at home has become one of the most ambitious promises in modern UK healthcare. Behind this simple phrase sit two powerful ideas: NHS virtual wards and hospital-at-home programmes — models designed to deliver acute-level care in patients’ homes using remote monitoring, clinical escalation pathways, and integrated multidisciplinary teams. In policy language, these services are meant to “free beds”, “reduce admissions”, and “transform capacity” across Integrated Care Systems (ICSs). In practice, however, the reality is more complex, more uneven, and far more dependent on workforce, social care, and digital maturity than the political rhetoric suggests.

The evidence base for treatment at home is not new. Systematic reviews from Asia, Europe, the US and Australia consistently show that hospital-at-home can be as safe as in-hospital care for well-selected patients, with comparable or lower mortality, stable or reduced readmissions, and—in some contexts—lower costs. Sentinel analyses (Leong 2021; Arsenault-Lapierre 2021; Cheng 2025) confirm that patients with chronic disease, acute medical conditions, and frailty can often be managed effectively outside hospital, when teams are adequately staffed and escalation pathways function reliably.

More recent evaluations of digital-enabled treatment at home, including NHS virtual wards, paint a more nuanced picture. Reviews such as Shi et al. (BMC Medicine, 2024) show that the digital layer itself does not guarantee better outcomes. Clinical safety appears broadly comparable to standard care, but results depend heavily on staffing intensity, data quality, and local system integration — a finding echoed by qualitative reviews (Cucurachi 2025; CADTH 2024). Importantly, NHS England’s own commissioned evaluations highlight wide variation between ICSs: some virtual wards operate as genuine acute alternatives, while others resemble extended community care packages with lighter clinical oversight.

The disparity in standards is now one of the most significant and under-discussed issues in the field. Across England, an older adult on a “virtual ward” in Surrey may receive high-frequency physiological monitoring, consultant oversight and daily MDT review. Meanwhile, a similar patient in parts of the Midlands may receive infrequent remote contact, limited escalation capability, and inconsistent digital documentation. The same model name, yet fundamentally different levels of care — with implications for clinical risk, equity, patient experience, and cost-effectiveness.

Digital health companies like Cera, Intelligent Lilli, and a growing ecosystem of UK innovators illustrate both the potential and the limitations of the digital shift. When implemented well, digital monitoring can reduce “failure demand”, detect deterioration earlier, streamline caseload management, and support community teams under extreme pressure. But without proper pathway redesign — or without social care capacity to receive patients — these digital tools often add parallel burdens: duplicated documentation, extra dashboards for clinicians to check, and new responsibilities loaded onto unpaid carers at home.

All of this unfolds against a system under immense structural strain. Bed occupancy remains at 95–98%, ICSs face thousands of patients medically fit for discharge but stuck in hospital, and Section 75 pooled budgets struggle to keep pace with demand. NHS productivity is still 7–8% below pre-pandemic levels, despite billions invested in digital transformation. In that environment, the question is no longer whether technology or treatment-at-home models are promising, but whether they actually deliver measurable gains in safety, bed-days saved, avoided admissions, reduced length of stay, and overall system cost.

This piece examines what the sentinel evidence truly shows, why results vary so widely across England, and what NHS leaders, ICSs, and digital-health innovators must do differently if treatment at home is to fulfil its potential — rather than becoming another well-intentioned idea unable to overcome the structural realities of the system.

What the Meta-Analyses Really Show About Treatment at Home

The strongest research on treatment at home comes from more than a decade of hospital-at-home and early supported discharge studies. These programmes existed long before virtual wards, but they share the same idea: give safe clinical care in a patient’s home, reduce pressure on hospitals, and maintain good outcomes. To see whether the NHS shift toward treatment at home is justified, we need to look at what the major meta-analyses actually show.

1.1 Treatment at home delivers outcomes similar to hospital care

Across many international studies, treatment at home performs as well as inpatient care for the right patients.

What the evidence shows:

Mortality: Most large reviews report no increase in deaths when patients receive care at home. In some groups, such as older adults or people with chronic lung disease, mortality is slightly lower.
Readmissions: Many studies find similar or reduced readmission rates, especially for COPD, heart failure and older frail patients.
Length of stay: When patients move home sooner under a structured programme, hospital length of stay falls without harming safety.

Together, these findings explain why the NHS is investing in treatment at home. When the right patients are chosen and the right clinical support is in place, hospital-level care can be delivered safely outside hospital walls.

1.2 Treatment at home can save money — but only with strong community services

Meta-analyses also explore costs. The results are encouraging, but only under the right conditions.

Treatment at home is most cost-effective when:

hospital care is expensive compared with home-based care
community nurses and home-care teams have capacity
discharge-to-assess pathways work smoothly
rapid-response escalation routes exist and are staffed

If those conditions are missing, the economics change. Instead of saving money, treatment at home moves workload to families, GPs and stretched community teams. This risk is especially relevant in the NHS, where community services have faced years of workforce shortages and where social care capacity remains a major blocker to safe discharge.

1.3 Technology is useful, but clinical intensity matters more

Many assume digital tools drive the success of modern treatment-at-home models. However, the large reviews show something different:

The digital layer does not guarantee better outcomes.
The intensity and quality of clinical care do.

Head-to-head comparisons of traditional hospital-at-home and digital-enabled virtual wards show:

no consistent difference in mortality
no reliable improvement in early escalation
no strong evidence that remote monitoring alone prevents deterioration
wide variation depending on staffing levels, training and governance

This explains why NHS virtual wards vary so much across ICSs. The clinical model is the main driver of outcomes; the technology simply supports it.

1.4 Treatment at home works best for specific patient groups

Across the meta-analyses, certain groups consistently benefit most:

people with milder frailty
stable patients leaving hospital after acute illness
those with COPD or respiratory flare-ups
people with heart failure needing stabilisation
selected post-operative patients

However, treatment at home is not suited to:

high-acuity or unstable patients
people with complex multi-morbidities needing frequent review
patients without safe home environments
individuals who cannot manage self-care or have no support

In practice, these boundaries are sometimes blurred in the NHS, which contributes to the uneven results seen across ICSs.

1.5 The hidden workload on families and unpaid carers

A recurring theme in many reviews — especially those focused on older adults — is that treatment at home often shifts work and responsibility away from hospitals.

Families and unpaid carers may take on:

daily monitoring
medication management
help with eating and drinking
mobilisation and fall prevention
spotting deterioration
reporting symptoms across multiple channels

In several UK evaluations, carers describe the experience as “the hospital in our front room”.
This matters for two reasons:

It changes the true cost of treatment at home.
It raises questions about equity, especially in ICSs where many families already face high levels of deprivation or health insecurity.

2. Why Treatment-at-Home Outcomes Vary So Widely Across ICSs

Although the evidence for treatment at home is strong, real-world results across England vary far more than the national guidance suggests. Some ICSs deliver safe, well-staffed, responsive home-based care. Others struggle with thin workforce models, weak social-care capacity, limited digital maturity, and unclear escalation routes. These differences create a national picture where the label “treatment at home” can describe two completely different levels of service.

Several factors drive this variation.

2.1 Different levels of staffing and clinical oversight

The largest performance gap between ICSs comes from how teams are staffed.

High-performing treatment-at-home services typically include:

daily multidisciplinary review
senior clinical decision-makers available at short notice
rapid access to diagnostics
clear escalation protocols
strong links between community, acute, and social-care teams

In contrast, some ICSs operate lighter models:

infrequent remote check-ins
limited access to night-time escalation
fewer community nursing hours
weaker links with primary care

These weaker models can still be safe for the right patients, but they do not produce the same system impact, particularly on length of stay or avoidable readmissions.

2.2 Uneven digital maturity and data quality

Treatment at home relies on good information flow. But ICSs vary widely in:

electronic patient record integration
device reliability
remote-monitoring platforms
alert thresholds
staffing of monitoring hubs
workload triage tools

High-performing ICSs tend to have interoperable systems, meaning data from virtual wards, community teams, and hospital teams appear in one place.

Other ICSs still use:

paper notes
manual triage
duplicated documentation
non-integrated remote-monitoring dashboards
slow escalation pathways

This difference alone can change outcomes. A stable frailty patient with good digital oversight will often avoid unnecessary readmission. A similar patient monitored through fragmented systems may deteriorate without timely review.

2.3 The social-care gap changes everything

No factor affects treatment-at-home outcomes more than social-care capacity.

ICSs with:

strong home-care providers
rapid reablement
local authority investment
functioning Section 75 pooled budgets
coordinated discharge-to-assess (D2A) hubs

…are able to move patients home sooner, keep them safe, and maintain independence.

ICSs without these structures face:

long waits for home-care packages
delayed discharges
increased workload for unpaid carers
higher risk of re-admission
less predictable treatment-at-home caseloads

This explains why some ICSs report good results on bed-days saved, while others see only modest impact. Treatment at home cannot succeed without social care, regardless of how strong the clinical model is.

2.4 Variation in governance, risk frameworks and safety processes

Some ICSs run treatment-at-home services with:

daily clinical governance meetings
formal risk assessments
clear clinical inclusion and exclusion criteria
24/7 escalation to acute teams
senior oversight of monitoring hubs

Others report:

less defined criteria
inconsistent risk triage
unclear lines of responsibility
delayed handovers between teams
patchy weekend coverage

This variation directly affects outcomes and patient experience. It also shapes staff confidence, which is a major driver of admission decisions and early escalation.

2.5 Differences in how digital tools are deployed

Companies such as Cera, Intelligent Lilli, and other UK digital-care providers are often used to support treatment at home. Their impact depends heavily on how ICSs adopt them.

Cera can deliver structured home visits, medication support, and risk-stratified monitoring — but only when:

referrals are timely
pathways are clear
data flows back to NHS teams
caseloads match staffing

Intelligent Lilli predicts deterioration risk and identifies behavioural changes early, but its benefits depend on:

monitoring frequency
integrated triage
community team responsiveness
user training

In ICSs with strong pathway design, these tools help reduce “failure demand,” support early detection, and reduce unnecessary readmissions. In under-resourced services, digital tools simply add alerts that teams cannot act on quickly.

2.6 Workforce pressure remains a fundamental constraint

Even the best treatment-at-home models depend on:

community nurses
rapid-response teams
therapists
social-care workers
carers
monitoring hub staff

But almost every ICS reports workforce shortages in these groups. Without real capacity, treatment at home becomes a limited-reach service, not a scalable alternative to hospital care.

This staffing variability is why two ICSs with identical digital systems can show completely different outcomes.

2.7 Local deprivation and home environments influence safety

Another factor often ignored is the home environment.

Patients living in:

poor-quality housing
multi-occupancy homes
limited heating or ventilation
unsafe environments
high deprivation
unstable family support

…are much harder to support safely at home.

Some ICSs have large numbers of these households, making treatment at home riskier and more complex, even with good clinical teams.

3. What NHS Data Shows About Treatment at Home in Practice

The ideal theory of treatment at home is compelling: fewer hospital beds tied up, more patients treated in their own homes, reduced length of stay, and lower system cost. But what do the real English NHS data show so far?

Capacity & Occupancy

According to the national data from NHS England, “virtual ward” services (also called treatment at home programmes) are now widely deployed across England. As of March 2025, there were 20 virtual ward beds per 100,000 GP-registered people and occupancy at roughly 76.2% (9,767 patients) across those beds.
Monthly data show the programme is expanding: capacity and occupancy statistics are published from April 2024 onward.

However, occupancy is not uniform: some ICSs report occupancy rates below the national average. For example, one ICB in October 2025 reported a 71.9% occupancy for its 11.2 beds per 100,000 population.

System Impact: Admissions, Bed-Days, Readmissions

An independent evaluation in the South East region (covering 29 virtual ward services) found that over 22,794 admission-avoidance attendances (annualised) were recorded across the services studied, with an estimated 9,165 avoidable non-elective (NEL) admissions per year.
This suggests real potential for reducing hospital admissions.

Yet the national evaluations raise caution. The 2025 Parliamentary POSTnote states that while virtual wards “can improve clinical outcomes and patient satisfaction, prevent hospital admissions and reduce the length of hospital stays”, there remains considerable uncertainty around funding, cost-effectiveness and variation in access/equity. POST+1

Patient and Carer Experience

A June 2025 report by the Strategy Unit (commissioned by NHS England) provides qualitative insight: many patients appreciated being at home, but unpaid carers described substantial shifts in workload and responsibility when a patient was treated at home rather than in hospital.

One example from a local service (Kingston & Richmond) showed that of 558 patients onboarded in 2024, the readmission rate was only ~8%, average stay was 8.7 days, and patient satisfaction was high.

Disparities and Variation

The variation across ICSs is stark. For example:

Some services treat older frail patients with sophisticated home-monitoring and daily MDT review; others treat less acute patients with lighter oversight.
Some ICSs report strong links between virtual wards and social-care discharge pathways; others still face severe delays in home-care packages.
Digital maturity and monitoring capability differ markedly.
These disparities mean that while some treatment-at-home services deliver system benefit, many remain under-optimised, limiting their effect on hospital capacity and waiting lists.

Implication for Capacity & Waiting Lists

Given the system context — bed occupancy at 95–98%, delayed discharges running into thousands every day — the data show treatment at home is helping, but not yet transforming the system.
While the South East evaluation estimated ~9,000 admissions avoided per year across 29 services, that number is modest relative to the scale of elective and urgent care backlogs in England.
Occupancy below 80% in many services suggests capacity is under-utilised, or models are conservative in patient selection. The POSTnote’s warning about “unequal access” and variation underscores that scaling-up remains a challenge.

Summary of What the NHS Data Shows

Treatment at home services are widely deployed: 20 beds per 100,000 population as of March 2025.
Occupancy is good (approx 75–80%) but variable across ICSs.
Evidence of admission avoidance and reduced readmissions is emerging (e.g., South East region data) but not yet nationalised.
Patient and carer experience is generally positive — but uptake comes with hidden workloads for carers.
Variation in staffing, social-care interface and digital infrastructure limits system-wide impact.
While promising, treatment at home is not yet delivering rapid, large-scale reductions in hospital bed-days, waiting lists or admissions at the national level.

4. Health Economics of Treatment at Home: Tariffs, Costs and System Reality

On paper, treatment at home should be an economist’s dream. If you can safely move a patient from a £400–£600 per day acute bed to a much cheaper home-based model, the savings appear obvious. The challenge is that NHS payment rules, workforce costs and overheads make the real picture far more complicated.

4.1 What one “bed day” actually costs the NHS

Average reference costs for an adult non-elective medical bed day in England typically land somewhere in the £350–£600 per day range once staff, estates, diagnostics and overheads are included (figures vary by trust and case-mix). The National Audit Office (NAO) estimated that the elective recovery plan sits within a system already absorbing billions of pounds in additional post-COVID costs, with a stretched workforce and inflationary pressure.

This is the upper bound against which treatment-at-home models are benchmarked. If a virtual ward or hospital-at-home model cannot deliver clinically safe care at a meaningfully lower per-day cost and free up the bed for another patient, it is not truly cost-saving — it is cost-shifting.

4.2 What treatment at home actually costs when done well

Real-world evaluations suggest that well-run hospital-at-home programmes can indeed be significantly cheaper than inpatient care:

An evaluation of the Central London Community Healthcare NHS Trust / West Hertfordshire “virtual hospital” reported that looking after patients remotely was around 80% cheaper than keeping them in hospital, and shortened admissions by nearly three days on average.
Cost-effectiveness analyses of home versus hospital management for selected conditions (for example, McCarroll et al. on paediatric diabetes ketoacidosis) found home-based models to be around £2,200 cheaper per patient episode, mainly due to reduced bed-days.
A 2024 scoping review on home care cost-effectiveness concluded that home-based models are often less costly, but only when sufficient professional support and clear protocols are in place; otherwise, costs are displaced to informal carers and primary care.

Taken together, these data support the idea that treatment at home can generate real savings — but only when it is delivered at sufficient scale, with robust staffing and a clear focus on substituting for genuine inpatient days.

4.3 How the NHS actually pays for treatment at home

Under the old national tariff, activity-based Payment by Results (PbR) meant trusts were paid per Finished Consultant Episode, with marginal rates for emergency admissions. Today, the NHS Payment Scheme uses a mix of:

blended payments for emergency care
block contracts and locally negotiated prices
best practice tariffs (BPTs) and non-mandatory prices for specific pathways
locally set prices for non-face-to-face activity, with a historic non-mandatory price of £23 for remote outpatient contacts retained as a reference point from earlier national tariff guidance.

Virtual wards and treatment-at-home models are generally funded via:

block / system-level budgets (ICS allocations)
time-limited central funding streams (e.g. £250m NHSE match-funding for virtual wards in 2023/24)
local agreements that treat virtual ward days as a substitute for admitted care, even though they do not always sit neatly in HRG or outpatient tariff structures

In practice, this means the traditional tariff signal is weak. Providers do not automatically earn more or less for moving a patient to treatment at home; instead, the incentive is indirect: free up physical capacity to meet elective targets and reduce costly escalation.

4.4 Why “cheap per day” is not enough

From a health-economic perspective, three questions matter more than the headline “cost per day”:

Did the model genuinely avoid an admission or shorten a stay?
If the patient would have been discharged anyway, the home-care costs are additive, not substitutive.
Was the freed bed used for another patient?
NAO and Public Accounts Committee analyses show elective recovery is stalling: in July 2025, around 7.4 million pathways were on the waiting list and 22% of patients waited more than six weeks for a diagnostic test.
If treatment at home does not translate into additional activity (more operations, more diagnostics), its opportunity value is lost.
Where did the workload go?
In many ICSs, the marginal cost of an extra virtual ward patient is borne by community nurses, GPs, unpaid carers and social care. Their costs and burnout risk rarely appear on a hospital balance sheet, but they are real.

A treatment-at-home model that looks cheap in a narrow trust-level spreadsheet can be net costly at system level if it simply pushes work to parts of the system that are already under-resourced.

4.5 Outpatient and remote-care coding: where does treatment at home sit?

Coding for treatment at home is not straightforward. Depending on local design, activity may be recorded as:

non-face-to-face outpatient attendances
community contacts under block-funded services
emergency care follow-up
“hospital at home” episodes under local service lines

National guidance for 2025/26 explicitly points commissioners back to the 2020/21 national tariff non-mandatory prices when they cannot agree local prices for non-face-to-face care.

For digital-heavy models that substitute for standard outpatient review — e.g. remote heart-failure titration, virtual fracture clinics, COPD early supported discharge — the economic question becomes:

Is a £X remote follow-up plus kit cheaper than a face-to-face review and additional bed-days, once staff time and re-admissions are counted?

This is where companies like Cera, Intelligent Lilli and others sit: they can support risk-stratified home review and “failure-demand” reduction, but only if commissioners and trusts recognise, code and pay for that activity as a productivity gain, not a soft add-on.

4.6 Treatment at home vs backlogs: macro-level impact

At macro level, the NAO has been blunt: even with billions invested in elective recovery and new models of care, the system is not on track to restore pre-pandemic waiting-time performance by 2025, and the Public Accounts Committee has recently reiterated that key recovery targets for elective and diagnostic care have been missed.

Against that backdrop, treatment at home delivers three economic truths:

Local cost-effectiveness is real
Done well, treatment at home can cut per-episode costs by hundreds or even thousands of pounds, mainly via reduced bed-days and hospital overheads.
System-level impact is constrained by bottlenecks
Bed-days freed by treatment at home only translate into backlog reduction if theatres, diagnostics, workforce and social care can absorb higher throughput. Where these are constrained, economic gains are blunted.
Equity and carer burden are part of the equation
In deprived ICSs, shifting more care into homes without parallel investment in housing, social care and carer support risks deepening inequalities — a cost rarely captured in traditional cost-effectiveness models, but very visible in real life.

In other words: treatment at home can be cost-effective at the micro level but underwhelming at the macro level, unless it is tied to hard capacity planning, realistic workforce models and deliberate use of coding and payment rules to reward genuine substitution, not token activity.

5. What Commissioners Should Demand Before Funding Any Treatment-at-Home Model

If treatment at home is going to move beyond pilots, PowerPoints and political ambition, commissioners need a clearer way to decide which models are worth backing. The truth is that many proposals look compelling on the surface: sleek dashboards, remote sensors, predictive alerts, and marketing promises of “freeing bed-days”. But most do not provide the type of evidence that ICSs, provider collaboratives or NHS England actually need to make safe, economically rational decisions.

This section sets out what commissioners should insist on, and how vendors can meet that bar.

5.1 Start with one question: What problem does this model solve?

Commissioners are rightly sceptical of technology that creates new work rather than removing it.
Every treatment-at-home proposal must answer, clearly and in one sentence:

Is this replacing an inpatient bed-day, or is it adding a new layer of activity?

If the answer is unclear, the economics collapse immediately.
The most common failure in virtual-ward business cases is that they present:

monitoring data
engagement metrics
patient sentiment
staff anecdotes

…but fail to quantify genuine substitution for hospital care.

Commissioners should demand a simple graphic:

X bed-days replaced or avoided
= Total patients × average days saved × safety threshold

Without this, nothing else matters.

5.2 Require proof of “substitution”, not adoption

Digital programmes often report adoption numbers (“8,000 patients onboarded”, “10,000 digital contacts”), but this means little. Commissioners need evidence of substitution:

avoided admissions
earlier discharge
reduced length of stay
reduced ED attendances
avoided face-to-face reviews
reduced failed follow-up
capacity released in diagnostic or therapy teams

If substitution is not shown, digital tools become additive cost, not cost-saving.

A simple commissioning rule is:

If the trust cannot show which part of their activity has reduced, the model is not substitutive.

5.3 Demand a “minimum data pack” for safety, outcomes and cost

Most vendors do not provide this unless pushed.

Commissioners should require six datasets:

1. Safety

mortality compared with expected baseline
deterioration episodes
escalation pathways used
safeguarding concerns
72-hour and 7-day post-discharge return rates

2. Clinical outcomes

symptom trajectories
disease-specific outcomes (e.g., COPD scores, heart-failure weights, NEWS2 trends)
readmission rates versus local historical comparators

3. Activity impact

length of stay (LOS) difference
inpatient bed-days saved
reduction in face-to-face visits
reduction in unnecessary diagnostic attendances

4. Economic data

cost per patient
staffing time per patient
equipment amortisation
downstream impact (GP time, community nursing time, carer burden)
cost-per-bed-day avoided

5. Operational performance

onboarding times
monitoring compliance
escalation times
response times
handover quality between acute and community

6. Equity & inclusion

use across deprivation quintiles
access issues in poor housing
carer availability
language and digital literacy barriers

If a vendor cannot deliver these, commissioners cannot perform a proper value or safety assessment.

5.4 Link the model to an HRG, tariff, or opportunity-cost unit

Treatment-at-home models often sit outside traditional coding.
To make investment rational, commissioners need to understand where the economic benefit appears:

avoided non-elective HRGs
reduced occupied bed-days
reduced outpatient follow-ups
reduced ED attendances
reduced delayed discharges
increased elective throughput (opportunity cost)

The best submissions now show:

For every 100 patients treated at home, ICS X can complete an additional Y elective procedures, worth £Z in backlog reduction.

This is the language that ICS CFOs, Directors of Finance and NHS England regional teams use.

5.5 Require model-of-care clarity: who escalates, who visits, who is accountable?

Many treatment-at-home services fail because the accountability lines blur.

Commissioners should demand:

a named clinical lead
clear escalation protocol
24/7 coverage plan
who handles deterioration alerts
who makes decisions at night
who owns documentation
who hands over to social care
who takes responsibility for readmissions

This clarity alone determines safety, workforce capacity and economic benefit.

5.6 Demand social-care alignment before signing anything

Treatment at home cannot succeed without functioning social care.

Commissioners should ask:

Are reablement teams engaged?
Is there home-care availability?
Are Section 75 pooled budgets active?
Are discharge-to-assess (D2A) flows established?
Who takes the carer burden?

If these pieces are weak, the model will underperform whatever its technology claims.

5.7 Require a realistic workforce model — not magical thinking

Vendors should provide:

staff hours per patient
average caseloads per nurse
required digital training
onboarding workload
escalation workload
documentation workload
estimated burnout or fatigue impact

If a model claims to “save nurse time” but increases documentation, calls, alerts or triage duration, commissioners should challenge it immediately.

5.8 Ask the only question that matters for ICS strategy

Does this model help us hit elective recovery targets, ED four-hour flow, 62-day cancer standards, and reduced length of stay?

If the answer is “not directly”, then treatment at home may still be valuable — but it is not an elective or urgent-care system lever. Commissioners need clarity about what it does move.

5.9 How vendors can win trust: speak in outcomes, not dashboards

Commissioners are tired of:

dashboards
engagement metrics
“AI-powered” claims
icons of devices
colourful pathway diagrams

The proposals that win are those that show:

hard outcomes
savings per patient
reduction in bed-days
reduction in readmissions
increased elective throughput
improved patient flow
staff time saved
better carer support
fewer unplanned visits

The winning formula is:

Evidence × Clarity × Cost × Capacity Impact

Not branding, not buzzwords, not sensors-for-sensors-sake.

6. The Future of Treatment at Home: What Needs to Change in 2026 and Beyond

The next phase for treatment at home in the NHS will not be defined by apps, dashboards or monitoring devices. It will be shaped by policy choices, workforce models, social-care reform, ICS maturity, and clear economic incentives. The science behind treatment at home is strong, but the system conditions that allow it to work are fragile. To move from promise to impact, several changes must happen.

6.1 Clear national standards to end the postcode lottery

Right now, treatment at home means very different things across England.
Some ICSs run well-staffed, clinically intensive services that deliver safe care and reduce bed-days. Others run lighter models that provide support, but not genuine substitution for hospital care.

To level this out, the NHS needs:

a national minimum service specification
consistent inclusion and exclusion criteria
clear rules on clinical oversight and escalation
agreed staffing ratios
a standard data set for outcomes and safety
unified language and coding for activity

Without this, treatment at home will continue to deliver uneven results, widening inequalities and weakening national evaluation.

6.2 Real investment in social care and reablement

Every serious evaluation ends with the same conclusion:

Treatment at home does not work without strong social care.

Even the best virtual ward cannot overcome:

shortages of home-care packages
delays in reablement start dates
housing insecurity
lack of carer support
fragile Section 75 pooled budgets

For treatment at home to scale, the NHS and local authorities must jointly invest in:

rapid reablement
home-care capacity
integrated discharge teams
shared funding models
home modifications for safe care

This is not a digital problem — it is a structural one.

6.3 Make clinical governance simple, repeatable and universal

Many ICSs still struggle with unclear lines of accountability.
A treatment-at-home model needs:

a named senior clinical lead
24/7 escalation clarity
structured handovers between acute and community teams
built-in safeguarding checks
rapid response and on-the-day review capability
reliable documentation across all teams

These rules should not vary wildly between ICSs.
Standardising clinical governance is one of the most powerful levers for safety, confidence and scale.

6.4 Focus digital investment on workflow, not devices

Most real value in treatment at home does not come from sensors.
It comes from removing friction:

fewer phone calls
fewer duplicated forms
faster triage
clearer escalation
better documentation
shared dashboards between acute, community, primary care and social services

The NHS should prioritise digital products that:

reduce “failure demand”
save staff time
speed up discharge
integrate with EPRs
automate routine tasks
support earlier intervention

Devices matter — but workflow matters more.

6.5 Use payment incentives that reward true substitution

Treatment at home thrives when the payment environment rewards:

reduced LOS
avoided admissions
faster recovery
more elective throughput
fewer delayed discharges
more efficient outpatient follow-up

The next evolution of the NHS Payment Scheme should:

include specific incentives for substitution activity
define virtual ward equivalents for admitted care
allow EPR-coded remote activity to count toward productivity
reflect opportunity cost savings at system-level

Without payment signals, models remain pilots instead of becoming part of normal care.

6.6 Build a workforce model that is achievable, not aspirational

Community workforce shortages are the most common limiting factor.
Treatment at home will only scale if workforce planning includes:

realistic caseloads
protected time for training
flexible staffing models across community and acute
digital roles within MDTs
support for carers
clearer integration with primary care

The NHS cannot expand treatment at home while asking staff to absorb more work with the same resources.

6.7 Use rigorous evidence standards to stop poor-quality pilots

For the first time since the Covid era, commissioners are asking for tougher evidence.
The next stage of treatment at home requires:

transparent reporting
agreed metrics
comparators
proper safety analysis
cost-per-bed-day avoided
demonstrated substitution
equity assessments

This is how commissioners will separate “real models of care” from marketing-heavy pilots.

6.8 The core message for 2026

Treatment at home is here to stay.
But it will only deliver the scale of impact the NHS needs if the system:

clarifies standards
aligns payment rules
builds social care capacity
strengthens workforce models
improves data flows
and demands real evidence

The truth from the evidence is clear:
treatment at home works — but only when the system around it works too.

**1. Shi, C. et al. (2024). Inpatient-level care at home delivered by virtual wards and hospital at home: a systematic review and meta-analysis. BMC Medicine.**

DOI: 10.1186/s12916-024-03312-3
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03312-3

**2. Leong, M.Q. et al. (2021). Comparison of hospital-at-home models: a systematic review. BMJ Open.**

https://bmjopen.bmj.com/content/11/1/e043285

3. UK Parliament POSTnote 744 (2025). Virtual Wards and Hospital at Home.

https://post.parliament.uk/research-briefings/post-pn-0744

4. NHS England. Virtual Wards (Hospital at Home) official programme page.

https://www.england.nhs.uk/virtual-wards

5. Health Foundation (2024). What do virtual wards look like in England?

PDF: https://www.health.org.uk/sites/default/files/2024-02/Virtual%20wards%20evidence%20brief.pdf

6. Strategy Unit (2025). Virtual Wards: Patients’ and Unpaid Carers’ Experiences.

https://www.strategyunitwm.nhs.uk/sites/default/files/2025-06/1171_Virtual_wards_final_report_June2025.pdf

7. PPL / NHS England South East (2024). South East Region Virtual Wards Evaluation – Summary.

https://www.england.nhs.uk/long-read/summary-of-south-east-region-virtual-wards-evaluation

**8. Norman, G. et al. (2023). Virtual wards: rapid evidence synthesis for older people. Age and Ageing.**

https://academic.oup.com/ageing/article/52/1/afac304/6997972

**9. Curioni, C. et al. (2023). Cost-effectiveness of home-care services for adults and older adults: systematic review. International Journal of Environmental Research and Public Health.**

https://www.mdpi.com/1660-4601/20/4/3373

**10. Jalilian, A. et al. (2024). Length of stay and economic sustainability of virtual ward care. BMJ Open.**

https://bmjopen.bmj.com/content/14/1/e081378

11. King’s Fund (2023). Hospital at home and virtual wards: what’s the evidence?

https://www.kingsfund.org.uk/publications/hospital-home-virtual-wards

12. NHS Confederation (2023). Virtual Wards: What the Data Tells Us.

https://www.nhsconfed.org/articles/virtual-wards-what-data-tells-us

13. Nuffield Trust (2023). Discharge to assess and capacity challenges – implications for virtual wards.

https://www.nuffieldtrust.org.uk/news-item/discharge-delays-why-is-social-care-struggling-to-keep-up

14. Fuller Stocktake (2022). Next Steps for Integrating Primary Care (Section on Virtual Wards & Care-at-Home Models).

https://www.england.nhs.uk/publication/next-steps-for-integrating-primary-care-fuller-stocktake-report

15. National Audit Office (2023). Elective Recovery and Hospital Capacity in England.

https://www.nao.org.uk/reports/nhs-england-management-of-the-elective-waiting-list

The Truth About Treatment at Home